Growth hormone secretagogue (GHS) peptide
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) that stimulates GH release via ghrelin receptor agonism. It is not FDA-approved for any indication and has limited published human clinical data. It is widely discussed in online fitness and anti-aging communities, often marketed as the 'safest' GHS due to its selectivity for GH release over cortisol and prolactin.
Track claims and source quality. Do not publish dosing, sourcing, or treatment instructions. Flag the 'safest GHS' framing as a community claim, not a regulatory or clinical consensus.
Ipamorelin is a first-generation ghrelin mimetic (GHS) pentapeptide identified in the late 1990s; the original pharmacology was published in the European Journal of Endocrinology (Raun et al., 1998).
It is not FDA-approved for any indication. Human clinical trial data in peer-reviewed literature is extremely limited compared to other GHS compounds like MK-677 or tesamorelin.
Online fitness and anti-aging communities frequently describe ipamorelin as the 'safest GHS' because preclinical data showed it did not significantly increase cortisol or prolactin — this framing reflects community interpretation, not regulatory endorsement.
Commonly stacked with CJC-1295 in telehealth and research-chemical contexts; neither compound is FDA-approved individually or in combination.
Evidence level: Community discussion
Sources: European Journal of Endocrinology (PubMed), U.S. Food and Drug Administration
The 'safest GHS' framing originates from preclinical selectivity data (minimal cortisol/prolactin release) and has been amplified by online communities. This is a community interpretation, not a regulatory determination. Flag explicitly.
Evidence level: Primary regulatory
Sources: U.S. Food and Drug Administration, U.S. Food and Drug Administration
No FDA approval record exists for ipamorelin. Products marketed as 'research use only' remain subject to FDA enforcement. Confirm on each review cycle.
Evidence level: Community discussion
Sources: U.S. Food and Drug Administration
The 'Ipamorelin + CJC-1295' stack is one of the most common peptide protocols discussed in fitness and telehealth communities. Track as a claim pattern; do not reproduce dosing instructions.
Free report
Use the same checklist Peptide Report uses to separate Ipamorelin claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Source records are stored in the repo and linked from each claim.
Raun et al. (1998) original pharmacology publication (PMID 9860070) describing ipamorelin as a pentapeptide growth hormone secretagogue with selectivity for GH release over cortisol and prolactin in animal models.
FDA warning letter discussing peptide products marketed online and the limits of research-use-only positioning.
FDA page summarizing bulk drug substances that may present significant safety risks in compounding contexts.
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog developed by ConjuChem with drug affinity complex...
Evidence reviewMK-677 (ibutamoren) is a non-peptide, orally active growth hormone secretagogue developed by Merck that mimics ghrelin t...
Evidence reviewSermorelin is a synthetic N-terminal fragment (1-29) of growth hormone-releasing hormone (GHRH) that was formerly FDA-ap...
Evidence reviewTesamorelin (brand name Egrifta) is an FDA-approved growth hormone-releasing hormone (GHRH) analog indicated for the red...
Regulatory watchStay informed